240 related articles for article (PubMed ID: 32314548)
21. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
[TBL] [Abstract][Full Text] [Related]
22. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma.
Whitcup SM; Stark-Vancs V; Wittes RE; Solomon D; Podgor MJ; Nussenblatt RB; Chan CC
Arch Ophthalmol; 1997 Sep; 115(9):1157-60. PubMed ID: 9298057
[TBL] [Abstract][Full Text] [Related]
23. Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
Zhang Y; Zou D; Yin J; Zhang L; Zhang X; Wang W; Zhang M; Zhou D; Zhang W
BMC Cancer; 2021 Feb; 21(1):183. PubMed ID: 33618687
[TBL] [Abstract][Full Text] [Related]
24. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
[TBL] [Abstract][Full Text] [Related]
25. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma.
Viaccoz A; Ducray F; Tholance Y; Barcelos GK; Thomas-Maisonneuve L; Ghesquières H; Meyronet D; Quadrio I; Cartalat-Carel S; Louis-Tisserand G; Jouanneau E; Guyotat J; Honnorat J; Perret-Liaudet A
Neuro Oncol; 2015 Nov; 17(11):1497-503. PubMed ID: 26014047
[TBL] [Abstract][Full Text] [Related]
26. The diagnostic and prognostic value of interleukin-10 in cerebrospinal fluid for central nervous system lymphoma: a meta-analysis.
Wang L; Luo L; Gao Z; Liu SF; Liu CJ; Ma DX; Chen JG; Cao WR; Yin AM; Xu JW; Wang SL; Zhuo DJ; Geng B; Zhao SS; Wang FY; Yang N; Guan LX; Gu ZY; Gao CJ
Leuk Lymphoma; 2017 Oct; 58(10):2452-2459. PubMed ID: 28278715
[TBL] [Abstract][Full Text] [Related]
27. Chemokine Ligand 13 (CXCL13) in Neuroborreliosis and Neurosyphilis as Selected Spirochetal Neurological Diseases: A Review of Its Diagnostic Significance.
Gudowska-Sawczuk M; Mroczko B
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32331231
[TBL] [Abstract][Full Text] [Related]
28. Has CXCL13 an added value in diagnosis of neurosyphilis?
Mothapo KM; Verbeek MM; van der Velden LB; Ang CW; Koopmans PP; van der Ven A; Stelma F
J Clin Microbiol; 2015 May; 53(5):1693-6. PubMed ID: 25788544
[TBL] [Abstract][Full Text] [Related]
29. The potential for CXCL13 in CSF as a differential diagnostic tool in central nervous system infection.
Masouris I; Klein M; Ködel U
Expert Rev Anti Infect Ther; 2020 Sep; 18(9):875-885. PubMed ID: 32479125
[No Abstract] [Full Text] [Related]
30. The chemokine CXCL13 in acute neuroborreliosis.
Senel M; Rupprecht TA; Tumani H; Pfister HW; Ludolph AC; Brettschneider J
J Neurol Neurosurg Psychiatry; 2010 Aug; 81(8):929-33. PubMed ID: 19965843
[TBL] [Abstract][Full Text] [Related]
31. CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma-Diagnostic, Therapeutic, and Prognostic Relevance.
Masouris I; Manz K; Pfirrmann M; Dreyling M; Angele B; Straube A; Langer S; Huber M; Koedel U; Von Baumgarten L
Front Neurol; 2021; 12():654543. PubMed ID: 33841320
[No Abstract] [Full Text] [Related]
32. Diagnostic utility of CSF soluble CD27 for primary central nervous system lymphoma in immunocompetent patients.
Murase S; Saio M; Andoh H; Takenaka K; Shinoda J; Nishimura Y; Sakai N; Takami T
Neurol Res; 2000 Jul; 22(5):434-42. PubMed ID: 10935213
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Value of sLR11 and sIL-2R in the Cerebrospinal Fluid for Malignant Central Nervous System Lymphoma.
Shimizu N; Nakao S; Hasunuma H; Nakaseko C; Shimizu T; Ebinuma H; Bujo H
Intern Med; 2024 Mar; ():. PubMed ID: 38432983
[TBL] [Abstract][Full Text] [Related]
34. CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma.
Ungureanu A; Le Garff-Tavernier M; Costopoulos M; Parratte T; Brinet A; Durand H; Gaultier C; Hurstel R; Alamome I; Sellal F; Ahle G
J Neurol; 2021 Aug; 268(8):2890-2894. PubMed ID: 33609156
[TBL] [Abstract][Full Text] [Related]
35. CXCL13 in Cerebrospinal Fluid: Clinical Value in a Large Cross-Sectional Study.
Erhart DK; Klose V; Schäper T; Tumani H; Senel M
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203597
[TBL] [Abstract][Full Text] [Related]
36. CXCL13 as a diagnostic marker of neuroborreliosis and other neuroinflammatory disorders in an unselected group of patients.
Wagner JN; Weis S; Kubasta C; Panholzer J; von Oertzen TJ
J Neurol; 2018 Jan; 265(1):74-81. PubMed ID: 29134272
[TBL] [Abstract][Full Text] [Related]
37. A systematic approach to the diagnosis of suspected central nervous system lymphoma.
Scott BJ; Douglas VC; Tihan T; Rubenstein JL; Josephson SA
JAMA Neurol; 2013 Mar; 70(3):311-9. PubMed ID: 23319132
[TBL] [Abstract][Full Text] [Related]
38. [CSF levels and diagnostic utility of cerebrospinal fluid beta2-microglobulin].
Caudie C; Bancel J; Dupont M; Matanza D; Poitevin F; Honnorat J
Ann Biol Clin (Paris); 2005; 63(6):631-7. PubMed ID: 16330382
[TBL] [Abstract][Full Text] [Related]
39. [Primary central nervous system lymphoma: a case report and evaluation of the diagnostic value of IL-10 level in the cerebrospinal fluid].
Mishima T; Tsuboi Y; Enomoto T; Higuchi MA; Tsugawa J; Yamada T; Tanaka T; Tsugu H; Hayashi H; Nabeshima K
Brain Nerve; 2012 Nov; 64(11):1347-51. PubMed ID: 23131747
[TBL] [Abstract][Full Text] [Related]
40. Significance of cerebrospinal fluid sIL-2R level as a marker of CNS involvement in acute lymphoblastic leukemia.
Lee W; Kim SJ; Lee S; Kim J; Kim M; Lim J; Kim Y; Cho B; Lee EJ; Han K
Ann Clin Lab Sci; 2005; 35(4):407-12. PubMed ID: 16254256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
